Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Arsenic stimulates angiogenesis and tumorigenesis in vivo.

Authors: Soucy, Nicole V; Ihnat, Michael A; Kamat, Chandrashekhar D; Hess, Linda; Post, Mark J; Klei, Linda R; Clark, Callie; Barchowsky, Aaron

Published In Toxicol Sci, (2003 Dec)

Abstract: Trivalent inorganic arsenic (arsenite, arsenic trioxide, As[III]) is currently being used to treat hematologic tumors and is being investigated for treating solid tumors. However, low concentrations of As(III) stimulate vascular cell proliferation in cell culture, although this has not been confirmed in vivo. Therefore, the hypothesis that As(III) enhances blood vessel growth (angiogenesis) and tumorigenesis was tested in two in vivo models of angiogenesis and a model of tumor growth. In the first, arsenite caused a dose-dependent increase in vessel density in a chicken chorioallantoic-membrane (CAM) assay. The threshold As(III) concentration for this response was 0.033 microM and inhibition of vessel growth was observed at concentrations greater than 1 microM. Mouse Matrigel implants were used to test the angiogenic effects of As(III) in an adult mammalian system. Mice were injected with 0.8-80 microg/kg As(III)/day over a three-week period. During the last two weeks, Matrigel plugs were placed on the abdominal wall. Low and high doses of As(III) were synergistic with fibroblast growth factor-2 (FGF-2) in increasing vessel density in the Matrigel assay, while a middle dose had no effect. To test the effects of As(III) on tumor growth, GFP-labeled B16-F10 mouse melanoma cells were implanted in nude mice, which subsequently received biweekly injections of 0.5-5.0 mg/kg As(III). Significant tumor growth and lung metastasis was seen in all animals, with the largest tumors occurring in animals treated with lower doses of As(III). These studies support the hypothesis and indicate that induction of angiogenesis, enhanced tumor growth, and metastasis are potential dose-dependent toxic side effects of arsenic therapies.

PubMed ID: 12970581 Exiting the NIEHS site

MeSH Terms: Allantois/blood supply; Allantois/drug effects; Allantois/pathology; Angiogenesis Inducing Agents/pharmacology*; Animals; Arsenites/pharmacology*; Blood Vessels/drug effects*; Blood Vessels/growth & development; Blood Vessels/pathology; Chick Embryo; Chorion/blood supply; Chorion/drug effects; Chorion/pathology; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 2/pharmacology; Lung Neoplasms/blood supply; Lung Neoplasms/secondary; Male; Melanoma, Experimental/blood supply*; Melanoma, Experimental/secondary; Mice; Mice, Nude; Neovascularization, Pathologic*; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Skin Neoplasms/blood supply*; Skin Neoplasms/pathology

to Top